All In Biotech

Drug Trial Radar · NCT03844217

Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers

Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers - The Macicop-Study

Last checked: Nov 20, 2026Latest source record: Aug 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Mar 7, 2019

Primary completion

Jul 16, 2019

Study completion Jul 16, 2019

Sponsor

Lead sponsor
University Hospital, Basel, SwitzerlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study investigates stimulation of the posterior pituitary gland by oral Macimorelin (a ghrelin receptor Agonist) to be a novel diagnostic test in the polyuria-polydipsia syndrome.

Conditions

  • Polyuria-polydipsia Syndrome

Interventions

  • Macimorelin 0.5mg/kg body weightDrug

    oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin

  • Macimorelin 0.75mg/kg body weightDrug

    oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Copeptin value (pmol/l), after intake of Macimorelin of 0.5mg/kg body weightTime frame: baseline blood exam (timepoint 0) and further blood collections after 30, 45, 60, 90 and 120 minutes after baseline blood collection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Basel Endocrinology, Diabetes and Metabolism

    Basel, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.